Aprilbio Co. Ltd.
AprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics. The company develops antibody drugs, double antibodies, long-acting antibody drugs, long-acting protein drugs, and ADC-applied antibodies. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases. The company was founded in 2013 and is h… Read more
Aprilbio Co. Ltd. - Asset Resilience Ratio
Aprilbio Co. Ltd. (397030) has an Asset Resilience Ratio of 89.71% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Aprilbio Co. Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Aprilbio Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩87.04 Billion | 89.71% |
| Total Liquid Assets | ₩87.04 Billion | 89.71% |
Asset Resilience Insights
- Very High Liquidity: Aprilbio Co. Ltd. maintains exceptional liquid asset reserves at 89.71% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Aprilbio Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Aprilbio Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Aprilbio Co. Ltd. (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Aprilbio Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 94.86% | ₩94.48 Billion | ₩99.60 Billion | +15.08pp |
| 2023-12-31 | 79.78% | ₩63.59 Billion | ₩79.70 Billion | -17.01pp |
| 2022-12-31 | 96.79% | ₩68.78 Billion | ₩71.06 Billion | +47.91pp |
| 2021-12-31 | 48.88% | ₩30.00 Billion | ₩61.38 Billion | +12.81pp |
| 2020-12-31 | 36.06% | ₩7.00 Billion | ₩19.41 Billion | -- |